Patrick Meyer Sauteur (Switzerland)

University Children's Hospital Zurich Division of Infectious Diseases and Hospital Epidemiology

Patrick Meyer Sauteur is a clinician scientist at the University Children's Hospital Zurich in Switzerland. He is a pediatrician and infectious diseases specialist and works as a consultant in pediatric infectious diseases. He obtained his MD degree at the University of Zurich and his PhD degree with honors at the Erasmus University of Rotterdam in the Netherlands. He leads the childhood pneumonia research group at the University Children’s Hospital Zurich. His research focuses on the pathogenesis, diagnosis, and treatment of pneumonia, particularly community-acquired pneumonia caused by Mycoplasma pneumoniae. The current aim of his research is to develop new diagnostic tools for M. pneumoniae infection and to assess the effect of antimicrobial treatment in the management of M. pneumoniae community-acquired pneumonia.

Presenter of 2 Presentations

Conference Calendar

MYCOPLASMA PNEUMONIAE GENOTYPES AND CLINICAL OUTCOME IN CHILDREN (ID 84)

Session Name

1890 - ORAL PRESENTATIONS 01: BACTERIAL INFECTION (ID 33)

Lecture Time

10:21 - 10:28

Room

Hall 01

Presenter

Patrick Meyer Sauteur (Switzerland)

Abstract

Abstract

Background

Mycoplasma pneumoniae (Mp) is a frequent cause of community-acquired pneumonia (CAP) in children. In addition, Mp can cause extrapulmonary disease, including mucocutaneous manifestations, or can be carried in the respiratory tract without causing any symptoms. Factors leading to the wide range of clinical outcomes associated with Mp infection are unclear. We investigated whether a specific genotype is associated with Mp virulence.

Methods

This is a prospective cohort study of Mp polymerase chain reaction-positive children, 3–18 years of age, with CAP (n=25), Mp-induced mucocutaneous disease (n=8), and without symptoms (carriers, n=6) from 2016–2017, from which respiratory specimens and/or Mp DNA extracts were available for extensive molecular characterization. In addition, Mp strains of their family members with respiratory tract infection (n=8) from 2016–2017, and children with Mp-induced mucocutaneous disease (n=7) during 2017–2020 were analyzed. Genotyping was performed using macrolide resistance determination, P1 subtyping, multilocus variable-number tandem-repeat analysis (MLVA), and multilocus sequence typing (MLST). Categorical and continuous variables were compared with the Fisher exact test and Mann-Whitney U test or pairwise Wilcoxon rank sum test with corrections for multiple testing, as appropriate.

Results

During the 2016–2017 study period, P1 subtype 1 (ST1) and 2 (ST2) were equally detected, but ST2 dominated in the first 6 months (n=20/26, 76.9%) and ST1 in the second 6 months (n=16/18, 88.9%) (P=0.00003). DNA levels did not differ between patients with specific outcomes. Macrolide resistance was detected in 1 (1.9%) strain (A2058G mutation). MLVA types included 3–5–6–2 (n=21/45, 46.7%), 3–6–6–2 (n=2/45, 4.4%), 4–5–7–2 (n=14/45, 31.1%), and 4–5–7–3 (n=8/45, 17.8%), and they correlated with P1 subtypes and MLST types. Mp strains were almost identical within families, but varied over geographic location. MLVA types were not associated with specific clinical outcomes, and differed in patients withmucocutaneous disease between 2016–2017 (3–5–6–2, n=5/8, 62.5%) and 2017–2020 (4–5–7–2, n=5/7, 71.4%) (P=0.02).